- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.95 Å
- Oligo State
- homo-tetramer
- Ligands
- 4 x NAI: 1,4-DIHYDRONICOTINAMIDE ADENINE DINUCLEOTIDE(Non-covalent)
- 4 x 9YA: 2-{3-([1,1'-biphenyl]-3-yl)-5-(cyclopropylmethyl)-4-[(4-sulfamoylphenyl)methyl]-1H-pyrazol-1-yl}-1,3-thiazole-4-carboxylic acid(Non-covalent)
9YA.2: 24 residues within 4Å:- Chain A: R.106, L.107, L.109, N.138, P.139, V.140, D.141, I.142, L.165, R.169, E.192, H.193, G.194, D.195, V.235, A.238, Y.239, I.242, T.248, L.323, I.326
- Ligands: NAI.1, EDO.3, EDO.6
17 PLIP interactions:17 interactions with chain A- Hydrophobic interactions: A:R.106, A:R.106, A:L.107, A:L.109, A:N.138, A:P.139, A:P.139, A:A.238, A:Y.239, A:I.326
- Hydrogen bonds: A:N.138, A:D.141, A:D.141, A:D.141, A:I.142
- Salt bridges: A:R.169, A:H.193
9YA.8: 24 residues within 4Å:- Chain B: R.106, L.107, L.109, N.138, P.139, V.140, D.141, I.142, L.165, R.169, E.192, H.193, G.194, D.195, V.235, A.238, Y.239, I.242, T.248, L.323, I.326
- Ligands: NAI.7, EDO.9, EDO.12
17 PLIP interactions:17 interactions with chain B- Hydrophobic interactions: B:R.106, B:R.106, B:L.107, B:L.109, B:N.138, B:P.139, B:P.139, B:A.238, B:Y.239, B:I.326
- Hydrogen bonds: B:N.138, B:D.141, B:D.141, B:D.141, B:I.142
- Salt bridges: B:R.169, B:H.193
9YA.14: 22 residues within 4Å:- Chain C: Q.100, R.106, L.109, V.110, N.138, P.139, V.140, D.141, I.142, L.165, R.169, E.192, H.193, G.194, D.195, A.238, Y.239, I.242, T.248, L.323
- Ligands: NAI.13, EDO.15
18 PLIP interactions:18 interactions with chain C- Hydrophobic interactions: C:R.106, C:R.106, C:L.109, C:V.110, C:N.138, C:P.139, C:P.139, C:I.142, C:A.238, C:Y.239
- Hydrogen bonds: C:N.138, C:D.141, C:D.141, C:I.142, C:T.248
- Salt bridges: C:R.169, C:H.193
- pi-Cation interactions: C:R.106
9YA.17: 22 residues within 4Å:- Chain D: Q.100, R.106, L.109, V.110, N.138, P.139, V.140, D.141, I.142, L.165, R.169, E.192, H.193, G.194, D.195, A.238, Y.239, I.242, T.248, L.323
- Ligands: NAI.16, EDO.18
18 PLIP interactions:18 interactions with chain D- Hydrophobic interactions: D:R.106, D:R.106, D:L.109, D:V.110, D:N.138, D:P.139, D:P.139, D:I.142, D:A.238, D:Y.239
- Hydrogen bonds: D:N.138, D:D.141, D:D.141, D:I.142, D:T.248
- Salt bridges: D:R.169, D:H.193
- pi-Cation interactions: D:R.106
- 10 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
EDO.3: 4 residues within 4Å:- Chain A: R.106, Y.239, I.242
- Ligands: 9YA.2
2 PLIP interactions:2 interactions with chain A- Hydrogen bonds: A:R.106, A:R.106
EDO.4: 3 residues within 4Å:- Chain A: R.177, E.229, V.230
1 PLIP interactions:1 interactions with chain A- Hydrogen bonds: A:R.177
EDO.5: 2 residues within 4Å:- Chain A: S.196, R.315
4 PLIP interactions:4 interactions with chain A- Hydrogen bonds: A:S.196, A:R.315, A:R.315
- Water bridges: A:S.196
EDO.6: 5 residues within 4Å:- Chain A: E.192, T.322, L.323, I.326
- Ligands: 9YA.2
3 PLIP interactions:3 interactions with chain A- Hydrogen bonds: A:E.192, A:T.322
- Water bridges: A:S.196
EDO.9: 4 residues within 4Å:- Chain B: R.106, Y.239, I.242
- Ligands: 9YA.8
2 PLIP interactions:2 interactions with chain B- Hydrogen bonds: B:R.106, B:R.106
EDO.10: 3 residues within 4Å:- Chain B: R.177, E.229, V.230
1 PLIP interactions:1 interactions with chain B- Hydrogen bonds: B:R.177
EDO.11: 2 residues within 4Å:- Chain B: S.196, R.315
4 PLIP interactions:4 interactions with chain B- Hydrogen bonds: B:S.196, B:R.315, B:R.315
- Water bridges: B:S.196
EDO.12: 5 residues within 4Å:- Chain B: E.192, T.322, L.323, I.326
- Ligands: 9YA.8
3 PLIP interactions:3 interactions with chain B- Hydrogen bonds: B:E.192, B:T.322
- Water bridges: B:S.196
EDO.15: 4 residues within 4Å:- Chain C: R.106, Y.239, I.242
- Ligands: 9YA.14
1 PLIP interactions:1 interactions with chain C- Hydrogen bonds: C:R.106
EDO.18: 4 residues within 4Å:- Chain D: R.106, Y.239, I.242
- Ligands: 9YA.17
1 PLIP interactions:1 interactions with chain D- Hydrogen bonds: D:R.106
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Rai, G. et al., Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH). J. Med. Chem. (2017)
- Release Date
- 2018-01-17
- Peptides
- L-lactate dehydrogenase A chain: ABCD
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
DB
DC
BD
B
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.95 Å
- Oligo State
- homo-tetramer
- Ligands
- 4 x NAI: 1,4-DIHYDRONICOTINAMIDE ADENINE DINUCLEOTIDE(Non-covalent)
- 4 x 9YA: 2-{3-([1,1'-biphenyl]-3-yl)-5-(cyclopropylmethyl)-4-[(4-sulfamoylphenyl)methyl]-1H-pyrazol-1-yl}-1,3-thiazole-4-carboxylic acid(Non-covalent)
- 10 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Rai, G. et al., Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH). J. Med. Chem. (2017)
- Release Date
- 2018-01-17
- Peptides
- L-lactate dehydrogenase A chain: ABCD
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
DB
DC
BD
B